Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-06-12 00:00:00 ET · period of report 2025-06-10 · accession 0001724521-25-000091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-12 | 2025-06-10 | RCUS | FALBERG KATHRYN E | Dir | A - Grant | $0.00 | +13.3K | 68.6K | +24% | $0 |
| D | 2025-06-12 | 2025-06-10 | RCUS | FALBERG KATHRYN E | Dir | A - Grant | $0.00 | +38.3K | 38.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-10 | A | A | 13,300 | $0.00 | 68,600 | D | — | — | (F1) Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| 2 | Derivative | Stock Option (Rights to Buy) | 2025-06-10 | A | A | 38,300 | $0.00 | 38,300 | D | $10.02 · — to 2035-06-09 | 38,300 Common Stock | (F2) The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |